These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17250598)

  • 1. Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions.
    Doviner V; Maly B; Reinhartz T; Vlodavsky I; Sherman Y
    Cytopathology; 2007 Feb; 18(1):13-9. PubMed ID: 17250598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. nm23 is expressed in reactive mesothelium and is not useful for detection of malignant cells in serous effusions.
    Zimmerman RL; Fogt F
    Oncol Rep; 2006 Jan; 15(1):85-8. PubMed ID: 16328038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic value of thrombomodulin immunolocalization in serous effusions.
    Ascoli V; Scalzo CC; Taccogna S; Nardi F
    Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
    Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
    Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
    Gulyás M; Hjerpe A
    J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of heparanase in gastrointestinal cancer (Review).
    Naomoto Y; Takaoka M; Okawa T; Nobuhisa T; Gunduz M; Tanaka N
    Oncol Rep; 2005 Jul; 14(1):3-8. PubMed ID: 15944760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase expression in gallbladder carcinoma and its correlation to prognosis.
    Wu W; Pan C; Yu H; Gong H; Wang Y
    J Gastroenterol Hepatol; 2008 Mar; 23(3):491-7. PubMed ID: 17524042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions.
    Metzgeroth G; Kuhn C; Schultheis B; Hehlmann R; Hastka J
    Cytopathology; 2008 Aug; 19(4):205-11. PubMed ID: 17573908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma.
    Peretti T; Waisberg J; Mader AM; de Matos LL; da Costa RB; Conceição GM; Lopes AC; Nader HB; Pinhal MA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):756-65. PubMed ID: 18617780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
    Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.
    Giarnieri E; Alderisio M; Mancini R; Falasca C; Ricci A; Mariotta S; Giovagnoli MR
    Oncol Rep; 2008 Feb; 19(2):483-7. PubMed ID: 18202798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis.
    Mikami S; Oya M; Shimoda M; Mizuno R; Ishida M; Kosaka T; Mukai M; Nakajima M; Okada Y
    Clin Cancer Res; 2008 Oct; 14(19):6055-61. PubMed ID: 18809970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions.
    Wu GP; Zhang SS; Fang CQ; Liu SL; Wang EH
    Cytopathology; 2008 Aug; 19(4):212-7. PubMed ID: 18699986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma.
    Zhang Y; Li L; Wang Y; Zhang J; Wei G; Sun Y; Shen F
    Biochem Biophys Res Commun; 2007 Jun; 358(1):124-9. PubMed ID: 17467664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cannibalism: diagnostic marker of malignancy.
    Gupta K; Dey P
    Diagn Cytopathol; 2003 Feb; 28(2):86-7. PubMed ID: 12561027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.